Hospira Symbiq Infusion System Touchscreen: Class 1 Recall – May Not Respond to Selection

by FDA on October 29, 2012

in MedWatch

Failure of touchscreen to respond to user input could result in a delay or interruption in therapy or over delivery or under delivery of medication.

This is a summary of an alert issued by MedWatch: The FDA Safety Information and Adverse Event Reporting Program. The link below will take you to the original notice.

View Full Details Of The Original MedWatch Notice Here.

Bookmark and Share

Leave a Comment

Previous post:

Next post: